From Deseret News archives:

Drug firm sued over generic action

Published: Thursday, Feb. 14, 2008 12:02 a.m. MST
 |  E-MAIL | PRINT | FONT + - 
PHILADELPHIA — Federal regulators sued Cephalon Inc. on Wednesday, accusing the company of illegally blocking the sale of low-cost generics to protect its biggest money-making drug.

The U.S. Federal Trade Commission has accused Cephalon of "anti-competitive conduct" by inhibiting generic competition against its drug Provigil. Regulators said the company paid four pharmaceutical firms more than $200 million to halt sales of generic versions of Provigil until 2012. Cephalon produces several products in Salt Lake City, including Actiq.

Provigil, which accounts for about half of Cephalon's total sales, treats excessive sleepiness in patients with sleep apnea, narcolepsy and shift-work sleep disorder.

"Cephalon prevented competition to Provigil by agreeing to share its future monopoly profits with generic drugmakers poised to enter the market, in exchange for delayed generic entry," FTC Bureau of Competition director Jeffrey Schmidt said in a statement. "Such conduct is at the core of what the antitrust laws proscribe."

But Cephalon defended its agreements, saying the deals reached in late 2005 and early 2006 settled patent infringement litigation.

"We believe they fully comply with both the spirit and letter of the antitrust laws," the company said in a statement.

Story continues below
Cephalon also said the settlements "confer a meaningful benefit to U.S. consumers by providing for the entry of generic modafinil three years early."

The FTC said the four drugmakers had been preparing to market their own generic versions of Provigil or had challenged the validity of the only remaining patent on the drug.

With Cephalon's settlement, the FTC said, it was able to get the drugmakers to stop the patent challenge. The four pharmaceutical firms are Teva Pharmaceuticals USA Inc., Ranbaxy Pharmaceuticals Inc., Mylan Pharmaceuticals Inc. and Barr Laboratories Inc.

Shares of Frazer-based Cephalon fell $1.03 to $57.44 on Wednesday.

Comments

You can be the first to comment on this story.

previousnext

Latest comments

BYU football: 5 keys to victory

Yes, that is true. And the 5th-year QB will learn how to be a good QB from...

@Bro Chuck's Rant's n Rave's: "If all citizens are to be treated equal,...

Which coach will take the 5th?

This article is about Kyle and Bronco. Lavell

I just intercepted Maxi Hall Sean Smith

I just intercepted Maxi again Paul Kruger

# of times a school went to BCS: Utah - 2 BYU - 0 (zero/zip/nil)

Every team wants to win every game..not possible A.D.

Running game key to BYU offense

And remember, the broncos lost last year to the 2nd best team in the MWC -...

Nobody here in the state truthfully cares if BSU wins or loses. It's an...

Letters: Reckless imbalance

To Hypocriy: Labor costs in Japan are higher than they are here, yet Japan...

Advertisements